Last reviewed · How we verify

GP2411 — Competitive Intelligence Brief

GP2411 (GP2411) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: G-CSF biosimilar. Area: Oncology.

phase 3 G-CSF biosimilar G-CSF receptor (GCSFR) Oncology Biologic Live · refreshed every 30 min

Target snapshot

GP2411 (GP2411) — Sandoz. GP2411 is a biosimilar of filgrastim that stimulates the production and release of neutrophils from bone marrow to support immune function.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
GP2411 TARGET GP2411 Sandoz phase 3 G-CSF biosimilar G-CSF receptor (GCSFR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (G-CSF biosimilar class)

  1. Sandoz · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GP2411 — Competitive Intelligence Brief. https://druglandscape.com/ci/gp2411. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: